Potential Weak Interaction
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence: Low
There was no clinically significant pharmacokinetic interaction when emtricitabine/tenofovir-DF was coadministered with tacrolimus. Coadministration increased tacrolimus AUC and Cmax by 4% and 3%; emtricitabine AUC and Cmax decreased by 5% and 11%, but tenofovir AUC and Cmax increased by 6% and 13%. No dose adjustment of tacrolimus is required but monitor renal function as appropriate since tacrolimus can affect renal function.